原发性HIV-1感染确诊后启动抗逆转录病毒治疗的时机对长期疗效的影响
基于法国ANRS PRIMO队列,比较原发性HIV感染后1个月内启动cART(77例)与感染后超过12个月启动(73例)患者的长期结局。立即治疗组HIV DNA下降更显著,持续平均差异为-0.6 log10 copies/10^6 PBMC;前4年CD4+计数和CD4:CD8比值改善更优,但末次访视(中位82个月)时两组免疫病毒学指标及炎症/活化标志物无差异,长期抑制性cART未能使炎症水平正常化。
要点
- 原发性HIV感染期间启动cART可长期缩小HIV储存库。
- 立即治疗在前4年CD4+计数和CD4:CD8比值改善更优。
- 长期病毒学抑制下炎症可能由非HIV因素驱动。
核心结论
- 原发性HIV感染期间启动抗逆转录病毒治疗可促进HIV储存库大小的长期降低。
- 在持续病毒学抑制的患者中,炎症可能由非HIV相关因素驱动。
研究设计与样本
- 从法国ANRS PRIMO队列选择治疗≥36个月且持续HIV RNA<50 copies/mL的患者。
- 立即治疗组77例在PHI诊断后1个月内治疗,延迟治疗组73例在感染后超过12个月治疗。
- 检测从PHI至末次访视的炎症生物标志物,以及末次访视时CD4+和CD8+ T细胞活化与超敏感血浆HIV RNA。
- 将炎症/活化水平与未感染对照比较,并建模cART期间CD4+计数、CD4:CD8比值和HIV DNA动态。
主要发现
- 立即治疗组HIV DNA水平下降比延迟治疗组更显著,导致持续平均差异为-0.6 log10 copies/10^6 PBMC。
- 立即治疗在前4年cART期间改善CD4+ T细胞计数和CD4:CD8比值。
- 末次访视(中位82个月)时两组CD4+计数、CD4:CD8比值、超敏感HIV RNA或炎症/活化标志物水平无差异。
- 长期抑制性cART未能使炎症水平正常化,且炎症水平与免疫病毒学标志物无关。
临床怎么用
- 对原发性HIV感染患者应尽早启动cART以长期缩小HIV储存库并改善早期免疫恢复。
- 即使长期病毒学抑制,仍需关注非HIV因素驱动的炎症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to determine the consequences of delayed human immunodeficiency virus type 1 (HIV-1) infection diagnosis by comparing long-term outcomes depending on the time of combination antiretroviral therapy (cART) initiation in patients diagnosed during primary HIV infection (PHI). METHODS: We selected patients from the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) PRIMO cohort, treated for ≥36 months, with sustained HIV RNA <50 copies/mL: 77 treated within 1 month following PHI diagnosis (immediate ART) and 73 treated >12 months after infection (deferred ART). We measured inflammatory biomarkers from PHI through the last visit on cART, and CD4+ and CD8+ T-cell activation and plasma ultrasensitive HIV RNA at the last visit. Inflammation/activation levels were compared with those of uninfected controls. We modeled CD4+ count, CD4:CD8 ratio, and HIV DNA dynamics on cART. RESULTS: The decrease of HIV DNA levels was more marked in the immediate than deferred ART group, leading to a sustained mean difference of -0.6 log10 copies/106 peripheral blood mononuclear cells. Immediate ART led to improved CD4+ T-cell counts and CD4:CD8 ratios over the first 4 years of cART. At the last visit (median, 82 months), there was no difference between groups in CD4+ counts, CD4:CD8 ratio, ultrasensitive HIV RNA, or inflammation/activation marker levels. Long-term suppressive cART failed to normalize inflammation levels, which were not associated with immunovirological markers. CONCLUSIONS: Antiretroviral therapy initiated during PHI promotes long-term reduction of HIV reservoir size. In patients with sustained virologic suppression, inflammation may be driven by non-HIV-related factors.
引用
- Novelli S, Lécuroux C, Avettand-Fenoel V, et al. Long-term Therapeutic Impact of the Timing of Antiretroviral Therapy in Patients Diagnosed With Primary Human Immunodeficiency Virus Type 1 Infection. Clin Infect Dis. 2018. PMID: 29211834. doi:10.1093/cid/cix1068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。